It involves an identified patient, a licensed prescriber, a clinical rationale, pharmacy accountability, and the possibility of follow-up and adverse-event evaluation
The widely repeated claim that Dihexa is "seven orders of magnitude more potent than BDNF" originates from that flagged McCoy paper and reflects an assay-specific in-vitro spine-density measurement picomolar Dihexa versus nanomolar BDNF in one assay not a millions-fold advantage in a living brain
The product also protects the skin from UV radiation and has an antiglycation effect, which helps prevent age-related changes
These products are not intended to diagnose, treat, cure, or prevent any disease, and no statement in this guide should be interpreted as a therapeutic claim or health recommendation
April 15, 2026: In the updated 503A document, the FDA announced it is removing BPC-157 (both BPC-157 acetate and BPC-157 free base) from Category 2 and scheduling a PCAC meeting for July 23, 2026
Frontiers in Cell and Developmental Biology, 9 (2021)